Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline

Alector (ALEC) will host a virtual research and development event on October 13, 2026, covering its wholly owned ABC-enabled pipeline.

Rhea-AI Summary

Alector (ALEC) will host a virtual research and development event on October 13, 2026, covering its wholly owned ABC-enabled pipeline. The webinar begins at 8:00 a.m. PT and will discuss Alector Brain Carrier, its platform for delivering therapies across the blood-brain barrier.

The agenda includes AL137, an anti-amyloid beta antibody, and the AL164, AL062 and ADP065 programs targeting tau, alpha-synuclein and NLRP3, respectively. Alector plans to present preclinical data on target reduction across multiple brain regions. A live question-and-answer session will follow the presentation, with an archived replay available for approximately 90 days.

Key Terms

siRNA, blood-brain barrier, fc effector function

3 terms

siRNA medical

"its tau siRNA program"

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

blood-brain barrier medical

"ABC blood-brain barrier platform"

A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.

fc effector function medical

"together with full Fc effector function"

Fc effector function describes the biological activities triggered by the Fc (fragment crystallizable) portion of an antibody after it binds its target; the Fc region engages immune-system components such as Fc receptors on white blood cells and complement proteins to produce outcomes like antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). These functions depend on the antibody isotype, Fc glycosylation and structure, and can be altered by protein engineering or Fc-receptor variation; Fc interactions also influence antibody half-life through the neonatal Fc receptor (FcRn).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Agenda to feature progress for AL137, its lead anti-amyloid beta antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) --  Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced management will host a virtual event to discuss the company's wholly owned ABC blood-brain barrier platform and programs in its ABC-enabled pipeline.

Details of the webinar are as follows:

Alector Pipeline Webinar: Advancing Next Generation Medicines for Neurodegeneration

Tuesday, October 13, 2026, at 8:00 a.m. PT

A live question and answer session will follow the formal presentation. To access the live webcast of this event, please register here, or visit "Events and Presentations" in the "Investors" section of the Alector website at https://investors.alector.com. An archived replay will be available for approximately 90 days following the presentation.

The event will feature:

• AL137: A next-generation anti-Aβ antibody targeting the pyroglutamate Aβ epitope, which, together with full Fc effector function, has been clinically validated. AL137 uses the unique TfR-binding domain of the Alector Brain Carrier (ABC), designed to limit immune-cell recruitment to reticulocytes while preserving full recruitment to Aβ plaques. This approach is intended to reduce hematologic risk without compromising plaque clearance. AL137 is designed for enhanced brain exposure, reduced ARIA risk, and monthly subcutaneous dosing.
• AL164, AL062 and ADP065: ABC-enabled siRNA programs targeting tau, α-synuclein and NLRP3, respectively. The company will present preclinical data demonstrating potent target reduction across multiple brain regions and explain how these brain-penetrant nucleic acid therapies are designed to address intracellular drivers of Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Each program is designed for once-quarterly subcutaneous dosing.
  
  

About Alector

Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, such as Alzheimer's disease and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.

Alector Contacts

Argot Partners (media)
David Rosen
646-461-6387
alector@argotpartners.com

Argot Partners (investors)
Laura Perry
alector@argotpartners.com